AVTX
Avalo Therapeutics, Inc.
There isn't enough reported data to score AVTX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
AVTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
AVTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVTX PE Valuation
AVTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AVTX Forward outlook
There aren't enough analyst estimates for AVTX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AVTX Earnings Per Share
AVTX and LLY do not have enough comparable growth data to identify a winner.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $59K | -69% |
| Q4 2024 | $192K | -66% |
| Q3 2024 | $249K | +5.5% |
| Q4 2023 | $571K | -36% |
| Q3 2023 | $236K | -98% |
| Q2 2023 | $643K | -38% |
| Q1 2023 | $475K | -60% |
| Q4 2022 | $896K | +309% |
AVTX's revenue has slid since its 2022 peak: $59,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -33461% | -26528 points |
| Q4 2024 | -6933% | -5592 points |
| Q3 2024 | -5165% | -3576 points |
| Q4 2023 | -1341% | -353 points |
| Q3 2023 | -1589% | -1616 points |
| Q2 2023 | -1112% | +33 points |
| Q1 2023 | -1851% | -73 points |
| Q4 2022 | -988% | +7214 points |
AVTX's operating margin was −33461% last quarter, down 31872 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.5M | +$4.8M |
| Q2 2026 | -$20M | -$8.6M |
| Q1 2026 | -$17.7M | -$8.2M |
| Q4 2025 | -$14.2M | +$798K |
| Q3 2025 | -$16.4M | -$4.8M |
| Q2 2025 | -$11.4M | +$4.9M |
| Q1 2025 | -$9.5M | -$3.3M |
| Q4 2024 | -$15M | -$12.3M |
AVTX has burned cash in almost every quarter: −$63M over the past year, against −$52M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AVTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
AVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +11.5M shares |
| 1 year | +408% | +44.2M shares |
AVTX has 55M diluted shares, up 408% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AVTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AVTX Net Leverage
AVTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 5.1 | Oversold |
AVTX's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AVTX PE vs Healthcare Sector
AVTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 27% below |
| 20 week MA | $15.4 | 50% below |
| 50 week MA | $15.7 | 51% below |
| 100 week MA | $12.2 | 37% below |
| 200 week MA | $96.8 | 92% below |
AVTX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AVTX on trend strength, trading above more of its moving averages.
AVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,774.4 | $7,920.0 | -46% |
| 2021 | $7,920.0 | $5,356.8 | -32% |
| 2022 | $5,356.8 | $1,202.4 | -78% |
| 2023 | $1,202.4 | $9.10 | -99% |
| 2024 | $9.10 | $8.33 | -8.5% |
| 2025 | $8.33 | $18.4 | +121% |
| 2026 YTD | $18.4 | $7.70 | -58% |
AVTX's yearly returns have swung widely, from +121% in 2025 to −99% in 2023. It's down 58% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AVTX on returns for 2026, with the stronger performance.